

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCY United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/700,239	11/03/2003	Andrew S. Pekosz	60005161-0114	3764	
- 26263 75	26263 7590 08/01/2006			EXAMINER	
SONNENSCHEIN NATH & ROSENTHAL LLP			SALVOZA, M FRANCO G		
P.O. BOX 061080 WACKER DRIVE STATION, SEARS TOWER			ART UNIT	PAPER NUMBER	
	CHICAGO, IL 60606-1080			1648	
			DATE MAILED: 08/01/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	10/700,239	PEKOSZ ET AL.
Office Action Summary	Examiner	Art Unit
	M. Franco Salvoza	1648
The MAILING DATE of this communication app Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be time ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	Lely filed the mailing date of this communication. O (35 U.S.C. § 133).
Status		
 Responsive to communication(s) filed on 01 Ma This action is FINAL. Since this application is in condition for allowant closed in accordance with the practice under E 	action is non-final. ce except for formal matters, pro	
Disposition of Claims	·	
 4) Claim(s) 1-25 and 95-98 is/are pending in the at 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-25, 95-98 are subject to restriction at 12 are subject. 	n from consideration.	
Application Papers		
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction in the original than the correction is objected to by the Examiner	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of 	have been received. have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	

DETAILED ACTION

Election/Restrictions

Species Election

This application contains claims directed to the following patentably distinct species:

The methods of 1 and 10 wherein the cell:

- 1. lacks all nucleocapsid proteins of the virus as recited in claims or
- 2. lacks at least one nucleocapsid protein selected from the group consisting of PA, PB1, PB2 and NP. If this species is elected, one of the nucleocapsid proteins the cell is lacking must further be elected.

The species are independent or distinct because the cell and proteins are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because the claim recites that the combination or cell can lack all nucleocapsid proteins. Thus, the combination may rely on any one of the subcombinations, or on the combination for patentability. The combination, therefore, does not require the particulars of any one of the subcombinations. Further, the subcombination or each of the nucleocapsid proteins has separate utility as structurally independent and distinct components of the influenza protein polymerase complex.

The nucleocapsid protein species are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct if they do not overlap in

Application/Control Number: 10/700,239

Art Unit: 1648

scope and are not obvious variants, and if it is shown that at least one subcombination is separately usable. In the instant case, the subcombination or each of the nucleocapsid proteins has separate utility as structurally independent and distinct components of the influenza protein polymerase complex. See MPEP § 806.05(d).

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-25 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Application/Control Number: 10/700,239

Art Unit: 1648

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to M. Franco Salvoza whose telephone number is (571) 272-8410. The examiner can normally be reached on M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

BRUCE R. CAMPELL, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Jun Compell

Page 4

Application/Control Number: 10/700,239

Art Unit: 1648

Page 5

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Patent Examiner July 20, 2006